실적분석 2026년 8월 4일

Pfizer ($PFE) Q2 2026 Earnings Analysis — Adjusted EPS and Revenue Both Beat, Full-Year Revenue Outlook Raised, Shares Slightly Weaker After Hours

Earnings Scorecard

Revenue: $15.034 billion (+3% YoY, vs. $14.405 billion estimate) ✅ Beat

EPS: Adjusted diluted $0.77 (vs. $0.68 estimate) ✅ Beat · GAAP diluted loss per share $0.04

Guidance: Revenue raised, adjusted EPS reaffirmed — 2026 revenue $60.5–62.5 billion (midpoint raised by $500 million), adjusted diluted EPS $2.80–3.00 (reiterated)

Stock Reaction: After hours -0.60% ($24.88) — as of 08-04 20:49 Korea time

The Positives

Adjusted EPS beat: Q2 adjusted diluted EPS of $0.77 topped the $0.78 estimate

Revenue beat and core product growth: Revenue of $15.034 billion; launched and acquired products grew +18% ex-FX

Full-year revenue guidance raised: Midpoint lifted by $500 million to $60.5–62.5 billion

Pfizer posted Q2 2026 (fiscal quarter ended June 28 for its US subsidiaries) revenue of $15.034 billion, up 3% from $14.653 billion a year earlier, or 1% on an ex-FX basis. The result topped the $14.405 billion consensus. Excluding the COVID-19 vaccine Comirnaty and the antiviral Paxlovid, ex-FX revenue grew 5%.

On the earnings side, the focus was on the adjusted view that strips out one-time and non-cash items. Q2 adjusted diluted EPS came in at $0.77, above the $0.68 consensus compiled before the release. Adjusted net income was $4.44 billion, roughly in line with the prior-year quarter.

Growth was driven by the new and acquired portfolio and key specialty medicines. Sales of launched and acquired products rose 18% ex-FX year over year, with standout ex-FX contributions from anticoagulant Eliquis (+19%), bladder-cancer treatment Padcev (+23%), lung-cancer therapy Lorbrena (+37%), and the Vyndaqel family for cardiac amyloidosis (+8%). The company raised the midpoint of its full-year revenue outlook to reflect expected outperformance in non-COVID products.

The Negatives

GAAP loss and large impairment: Net loss attributable to common shareholders of $248 million; ~$4.3 billion intangible-asset impairment

COVID-19 products plunge: Paxlovid -95% ex-FX, Comirnaty -34%

EPS guidance held, COVID outlook cut: Adjusted EPS guidance maintained; full-year COVID revenue cut to ~$4 billion

On a GAAP (reported) basis, the picture looks different. Q2 net loss attributable to common shareholders was $248 million, translating to a diluted loss per share of $0.04. The result reflects a shareholder-side net loss driven largely by a non-cash intangible-asset impairment charge of approximately $4.3 billion. The impairment includes about $3.8 billion tied to R&D assets following Phase 3 results for the lung-cancer candidate sigvotatup vedotin, and a $525 million write-down of Oxbrita technology rights after management concluded there is no path back to the US market.

COVID-19-related products continue to roll off. Paxlovid revenue fell 95% ex-FX on lower infections and reduced government purchases in some countries, while Comirnaty dropped 34% on a smaller return accrual adjustment and a narrower US vaccination recommendation. The company cut its 2026 COVID-product revenue expectation to roughly $4 billion from about $5 billion previously.

Full-year adjusted diluted EPS guidance was reiterated at $2.80–3.00. Non-COVID strength created some room on the earnings side, but management framed it as absorbing a one-time R&D expense in Q3 tied to the Innovent Biologics collaboration (~$650 million, or about $0.10 per share). Revenue went up while the EPS range stayed put, making it hard to argue the print fully met the market's bar for quality growth.

What Management Said

Management framed the quarter as a strong period that delivered on financial commitments, pointing to launched and acquired product performance and the obesity and oncology portfolios as the pillars of medium-term value. CEO Albert Bourla highlighted that launched and acquired products performed well, the obesity program has momentum, and oncology is a strength. Incoming interim CFO Cacil Gongas expressed confidence in the guidance revision, citing global commercial execution and operating efficiency — particularly the 18% ex-FX growth in launched and acquired products.

The guidance message struck a balanced tone: lift revenue, defend the EPS range, and absorb one-time costs. The company raised the revenue midpoint by $500 million by expecting about $1.5 billion more from non-COVID products while cutting roughly $1 billion from COVID expectations, and at the same time expanded its cost-reduction program to a cumulative additional ~$2.5 billion over 2027–2029, combining about $1.5 billion in cost-of-goods savings with roughly $1 billion in SI&A reductions. On capital return, however, 2026 share buybacks were not included in the guidance; in the first half the company returned capital primarily through dividends of about $4.9 billion ($0.86 per share).

Market Reaction and What to Watch Next

The numbers themselves — adjusted EPS and revenue both beat, with a higher full-year revenue outlook — were constructive, but the after-hours response was a tepid decline. The market had already partly priced in a non-COVID recovery, while the EPS guidance was only reaffirmed, the COVID revenue outlook was cut again, and a large impairment tied to a Phase 3 failure and a product withdrawal rekindled debate about earnings quality. The interim CFO transition and the full quarter-3 hit from the Innovent deal costs also cap near-term momentum.

Watch whether the pace of growth in launched and acquired products and non-COVID franchises like Eliquis, Padcev, and Lorbrena holds into Q3.

Phase 3 initiation and interim data for the obesity candidate verubena tide and key late-stage oncology candidates will shape medium-term growth expectations.

Monitor how the company defends its full-year adjusted EPS range while absorbing the Innovent one-time cost and how additional savings flow through to the actual earnings trajectory.